Episode description

Drugmakers in the red, as CMS releases its drugs that are subject to medicare price negotiations. The names getting hit the hardest, and how its impacting the weight loss drug race. Plus Is Intel on the market? M&A rumors helping boost the stock, but who could be the buyer? What a deal could mean for the beaten down chipmaker, and the impact on the tech space.

Fast Money Disclaimer